TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07601243: A Phase 1, Multicenter, Open-Label Clinical Study to Evaluate the Safety and Tolerability of GS-2426 in Participants With Advanced MTAP-Deleted Solid Tumors

Sponsor: Gilead Sciences · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 174 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07601243 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07601243 Rescue Dossier →